COVID-19

Vaccine makers should license technology to overcome ‘grotesque’ inequity – WHO

Reuters

This is AI generated summarization, which may have errors. For context, always refer to the full article.

Vaccine makers should license technology to overcome ‘grotesque’ inequity – WHO

CHECK. A worker performs a quality check in the packaging facility of Chinese vaccine maker Sinovac Biotech.

Thomas Peter/Reuters

(1st UPDATE) 'The inequitable distribution of vaccines is not just a moral outrage. It's also economically and epidemiologically self-defeating,' says WHO Director-General Tedros Adhanom Ghebreyesus

More producers of COVID-19 vaccines should follow AstraZeneca’s lead and license technology to other manufacturers, the World Health Organization’s head said on Monday, March 22, as he described continuing vaccine inequity as “grotesque.”

AstraZeneca’s shot, which new US data on Monday showed was safe and effective despite some countries suspending inoculations over health concerns, is being produced in various locations including South Korea’s SKBioScience and the Serum Institute of India.

WHO Director-General Tedros Adhanom Ghebreyesus called for more manufacturers to adopt this model to boost supplies, including for the COVAX vaccine sharing program seeking to speed more shots to developing countries.

“The gap between number of vaccines administered in rich countries and the number administered through COVAX is growing and becoming more grotesque every day,” Tedros told a news conference.

“The inequitable distribution of vaccines is not just a moral outrage. It’s also economically and epidemiologically self-defeating.”

Must Read

Vaccine nationalism puts world on brink of ‘catastrophic moral failure’ – WHO chief

Vaccine nationalism puts world on brink of ‘catastrophic moral failure’ – WHO chief

But the head of an industry group representing Big Pharma rejected Tedros’ criticism as showing “a lack of understanding for the complexity of vaccine manufacturing and the global supply chain.”

Thomas Cueni, director general of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) said in a statement that scaling up of vaccine production was on track thanks to partnerships among vaccine makers in the developing and developed world collaborating “in a manner never seen before”.

“Technology transfer and collaborations are taking place on a massive scale,” Cueni said, citing deals between AstraZeneca and Novavax with the Serum Institute in India, and between Johnson & Johnson with Aspen Pharma in South Africa and Biologic E in India.

Earlier, AstraZeneca released interim data showing its vaccine, developed with Oxford University, was 79% effective in preventing symptomatic COVID-19 and posed no increased risk of blood clots.

WHO chief scientist Soumya Swaminathan called it a “very good vaccine for all age groups.”

Sweden, Norway, Finland, and Denmark have extended suspensions of AstraZeneca’s shot as investigations continue into rare blood clotting events.

Still, WHO officials said African countries getting the vaccine via COVAX are moving ahead.

“They did ask a lot of questions but the demand for the vaccine is extremely high,” said WHO senior adviser Bruce Aylward.

Must Read

Rich nations stockpiling a billion more COVID-19 shots than needed – report

Rich nations stockpiling a billion more COVID-19 shots than needed – report

It remains possible for COVAX to hit a second-quarter goal of delivering 300 million doses, Aylward said, while acknowledging “teething problems,” with SKBioSciences and the Serum Institute hard pressed to satisfy COVAX orders.

“We simply cannot get enough vaccine,” Aylward said. “We’re hoping both companies will be able to scale up and keep up with the rate of deliveries we’re aiming for.” – Rappler.com

Add a comment

Sort by

There are no comments yet. Add your comment to start the conversation.

Summarize this article with AI

How does this make you feel?

Loading
Download the Rappler App!